4-(4-氨基苯基)-3-甲基-4-氧代丁酸乙酯 | 133209-06-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-氨基苯基)-3-甲基-4-氧代丁酸乙酯
• 英文名称: ethyl 4-(4-aminophenyl)-3-methyl-4-oxobutyrate
• 英文别名: ethyl 3-(4-aminobenzoyl)butyrate；Ethyl 4-(4-aminophenyl)-3-methyl-4-oxobutanoate
• CAS: 133209-06-0
• 化学式: C₁₃H₁₇NO₃
• 分子量: 235.283
• InChiKey: UXNFVYDIESWZQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  69.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-氨基苯基)-3-甲基-4-氧代丁酸乙酯 在 sodium sulfide 、 溴 、 potassium carbonate 作用下， 以 溶剂黄146 为溶剂， 反应 15.0h， 生成 3-Methyl-4-oxo-4-(3-oxo-3,4-dihydro-2H-benzo[1,4]selenazin-7-yl)-butyric acid ethyl ester
  参考文献：
  名称：

  Heteroatom analogs of bemoradan: chemistry and cardiotonic activity of 1,4-benzothiazinylpyridazinones

  摘要：

  A series of close analogues of the potent, long-acting cardiotonic bemoradan (2a) was synthesized and examined in both in vitro and in vivo test systems. Changing the oxygen heteroatom at the 1-position of the benzoxazine ring of bemoradan to sulfur gave 4a, a more potent enzyme inhibitor and in vivo cardiotonic compound by the iv route. Intraduodenal administration of bemoradan, however, showed a superior response compared to its sulfur analogue, possibly due to oxidation of sulfur followed by a facile Pummerer rearrangement. Model studies were performed to examine the effect of the oxidation state of sulfur. Lack of a heteroatom at the 1-position, 3a (Y-590), afforded a compound with activity and potency very similar to those of bemoradan while the 1-selena compound gave a much less potent analogue 5. Analogues having a methyl group on the 4-nitrogen (2b, 3b, and 4b) were less potent than the desmethyl compounds, but all of these compounds have potent PDE III inhibiting activity and the ability to increase cardiac force in an anesthetized dog preparation when given iv.

  DOI：

  10.1021/jm00079a023

文献信息

• Pyridazinone derivatives
  申请人：Smith Kline & French Laboratories Limited

  公开号：US04962110A1

  公开（公告）日：1990-10-09

  The invention relates to 2-aminopyrimidinone derivatives that have utility as cardiac stimulants. A compound of the invention is 6-[4-(1,4-dihydro-4-oxo-2-pyrimidinylamino)phenyl]-5-methyl-4,5-dihydro-3( 2H)-pyridazinone.

  本发明涉及2-氨基嘧啶酮衍生物，其具有作为心脏兴奋剂的效用。本发明的化合物是6-[4-(1,4-二氢-4-氧代-2-嘧啶基)苯基]-5-甲基-4,5-二氢-3(2H)-吡啶酮。
• Cyanoalkanimidamido compounds
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0199465A2

  公开（公告）日：1986-10-29

  Compounds of the formula (I): and pharmaceutically acceptable salts thereof are described, wherein R' is hydrogen or methyl and R2 is C2-4 alkyl. These compounds have inotropic, vasodilator, bronchodilating and platelet aggregation inhibiting properties. Pharmaceutical compositions are described as are methods of use. Intermediates and processes for the preparation of the compounds of the formula (1) are described.

  描述了式 (I)： 及其药学上可接受的盐类，其中 R' 为氢或甲基，R2 为 C2-4 烷基。 这些化合物具有肌力、血管扩张、支气管扩张和血小板聚集抑制特性。此外，还介绍了药物组合物以及使用方法。还介绍了制备式（1）化合物的中间体和工艺。
• 6-Phenyl-pyridazinyl compounds
  申请人：SMITH KLINE & FRENCH LABORATORIES LIMITED

  公开号：EP0208518B1

  公开（公告）日：1991-09-11
• US4766122A
  申请人：——

  公开号：US4766122A

  公开（公告）日：1988-08-23
• US4946842A
  申请人：——

  公开号：US4946842A

  公开（公告）日：1990-08-07